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sults:  During the 5-year follow-up [29,915 patient-years (PY)], 
183 patients had a stroke (incidence per 1,000 PY: 6.1 cases). 
In patients with PAD (n = 1,429) compared to those without 
PAD (n = 5,392), the incidence of all stroke types standard-
ized per 1,000 PY, with the exception of hemorrhagic stroke, 
was about doubled (for fatal stroke tripled). The correspond-
ing adjusted hazard ratios were 1.6 (95% confidence interval, 
CI, 1.1–2.2) for total stroke, 1.7 (95% CI 1.2–2.5) for ischemic 
stroke, 0.7 (95% CI 0.2–2.2) for hemorrhagic stroke, 2.5 (95% 
CI 1.2–5.2) for fatal stroke and 1.4 (95% CI 0.9–2.1) for nonfatal 
stroke. Lower ABI categories were associated with higher 
stroke rates. Besides high age, previous stroke and diabetes 
mellitus, PAD was a significant independent predictor for 
ischemic stroke.  Conclusions:  The risk of stroke is substan-
tially increased in PAD patients, and PAD is a strong indepen-
dent predictor for stroke.  Copyright © 2010 S. Karger AG, Basel 
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 Abstract 
 Background:  There is controversial evidence with regard to 
the significance of peripheral arterial disease (PAD) as an in-
dicator for future stroke risk. We aimed to quantify the risk 
increase for mortality and morbidity associated with PAD. 
 Methods:  In an open, prospective, noninterventional cohort 
study in the primary care setting, a total of 6,880 unselected 
patients  6 65 years were categorized according to the pres-
ence or absence of PAD and followed up for vascular events 
or deaths over 5 years. PAD was defined as ankle-brachial 
index (ABI)  ! 0.9 or history of previous peripheral revascular-
ization and/or limb amputation and/or intermittent claudi-
cation. Associations between known cardiovascular risk fac-
tors including PAD and cerebrovascular mortality/events 
were analyzed in a multivariate Cox regression model.  Re-
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These results were presented by R.L.H. at the International Stroke 
Conference in San Diego, Calif., USA, February 18–20, 2009.
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 Background 
 It is well known that individuals with peripheral arte-
rial disease (PAD) of the lower extremities are among the 
highest-risk vascular patients  [1, 2] . The presence of PAD 
is widely accepted as an indicator for generalized athero-
sclerosis, and the association between PAD and  cardio-
vascular mortality and morbidity can be regarded as con-
firmed  [3–8] .
 Patients with stroke or transient ischemic attack often 
have PAD  [9, 10] . However, it is still unclear whether PAD 
is also a good predictor for future  cerebrovascular disease 
(CVD). A number of previous studies have reported con-
flicting results  [11–14] , and epidemiological data in the 
primary-care setting are limited. Such studies are need-
ed, as the general physician holds a gatekeeper role in the 
diagnosis and management of PAD patients.
 Thus, the aim of the present study was to quantify the 
CVD (stroke) risk of PAD patients compared to those 
without PAD in a typical primary-care sample of un-
selected elderly patients. For the identification of PAD, 
the ankle-brachial index (ABI) was used which is the ra-
tio of anterior/posterior ankle systolic blood pressure to 
brachial systolic blood pressure. The ABI is in essence a 
screening-level assessment for PAD in the legs  [15, 16] .
 When 0.9 or lower, it is very sensitive and specific for 
obstruction compared with the gold standard angiogra-
phy  [17] or compared with a full vascular laboratory eval-
uation  [18] .
 Methods 
 Patients and Study Evaluations 
 The methods and design of the German Epidemiological Trial 
on Ankle-Brachial Index (getABI) have been described elsewhere 
in greater detail  [19, 20] . Briefly, the study is an open, noninter-
ventional prospective cohort study that is monitored. A total of 
344 general physicians (GPs) across Germany, who were trained 
and supervised by 34 vascular physicians in their vicinity, per-
formed the study. A prevalence assessment of primary-care at-
tendees, irrespective of their reason for seeing the doctor, was 
conducted within a prespecified week in October 2001. In each 
practice, the gender and age category of all patients attending the 
practice and seeing the doctor were recorded in a log file for each 
day of the week. The only exclusion criterion was life expectancy 
 ̂  6 months. A total of 20 (in exceptional cases up to 25) eligible 
patients fulfilling the inclusion criteria (age  6 65 years, patient 
being legally competent and able to cooperate appropriately and 
providing written informed consent) were recruited, preferably as 
evenly as possible over this week in order to avoid selection bias. 
The sex and age distribution of this elderly cohort (n = 6,880) was 
very similar to one of the general population ( 6 65 years) in Ger-
many, with a slight underrepresentation of the very old  [19] . The 
protocol was approved by the ethics committee of the Ruprecht-
Karls University Heidelberg, and all patients provided informed 
consent.
 As the study is purely observational, no recommendation was 
given to physicians on how to manage their patients, irrespective 
of PAD status.
 Examinations at Baseline 
 A short physical examination was performed at baseline. Med-
ical history assessment included the following conditions: (a) his-
tory of revascularization (coronary/at carotids) or myocardial in-
farction [myocardial infarction, coronary revascularization pro-
cedures, revascularization procedures on the carotid arteries (and 
no stroke)], (b) history of stroke, (c) history of peripheral revascu-
larization or amputation (due to PAD), i.e. a history of revascular-
ization procedures on the peripheral arteries, or amputation (mi-
nor and major form) of the lower extremities on account of PAD, 
(d) intermittent claudication (i.e. pain in the calf muscles while 
walking or during other exertion and disappearing within 10 min 
at rest), (e) risk factors, e.g. systolic blood pressure, diabetes, lipid 
disorders or smoking. Subjects were defined as having diabetes 
mellitus (i) if they had been assigned the clinical diagnosis by their 
physician and/or (ii) if their HbA 1c was  6 6.5% (criterion used in 
94 cases) and/or (iii) if they were receiving any oral antidiabetic 
drug and/or insulin at baseline. The  6 6.5% HbA 1c value is above 
the typically used upper reference value of 6.0% and is highly
specific for diabetes  [21, 22] . Subjects were defined as taking hy-
pertension medication, if they were receiving AT 1 receptor an-
tag onists and/or ACE inhibitors and/or diuretics at baseline.
As   -blockers and calcium channel blockers are often used in
indications other than hypertension (e.g. coronary heart disease, 
heart failure), we excluded them from the definition of hyperten-
sion. Subjects were defined as having lipid disorders (i) if they had 
been assigned the clinical diagnosis by their physician and/or (ii) 
if they were receiving statins and/or fibrates and/or (iii) if their 
total cholesterol was  6 200 mg/dl at baseline and/or (iv) if their 
triglyceride value was  6 150 mg/dl at baseline. All laboratory ex-
aminations were performed centrally. A cigarette smoking his-
tory was taken from all study subjects (never, current, past). In-
formation on atrial fibrillation was retrieved for stroke patients 
from patient charts and physician letters.
 PAD Definition 
 GPs were specifically trained by vascular physicians to per-
form ABI measurements under standardized conditions on the 
resting patient. Doppler measurements were done with the Kranz-
bühler 8-MHz device, General Electrics, Solingen, Germany. 
Blood pressure measurements and ABI calculations were per-
formed according to the recommendations of the American 
Heart Association  [23, 24] . The ABI was calculated separately for 
each leg by dividing the higher of the 2 systolic pressures (tibial 
posterior and anterior artery) above the ankle, by the average of 
the right and left brachial artery pressures. If there was a discrep-
ancy  6 10 mm Hg in blood pressure values between the two arms, 
the higher reading was used for the ABI. The lower of the two ABI 
values was used for analyses.
 PAD was defined as either symptomatic  or asymptomatic 
PAD. Asymptomatic PAD was defined as resting ABI  ! 0.90  [1, 2, 
24] , with absence of prior peripheral arterial events or clinical 
symptoms indicative of intermittent claudication. Symptomatic 
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PAD was defined as intermittent claudication and/or history of 
peripheral vascular revascularization and/or limb amputation 
due to PAD. Fifty-nine patients with incompressible arteries 
(Mönckeberg sclerosis) as indicated by an ABI  1 1.5 were excluded 
(52.5% of these were diabetic), as in other studies, to avoid mis-
classification  [25, 26] , for a total of 6,821 patients in the analyses. 
Cases with missing ABI values (n = 8) and no past peripheral 
events or intermittent claudication were classified as patients 
without PAD.
 Definition of Stroke Events during Follow-Up 
 Information on patients’ deaths and vascular events was ob-
tained from the participating GPs in regular prespecified inter-
vals (at 6 months, and at 1, 3 and 5 years) on case record forms 
detailing the event. At the 5-year-follow-up visit, GPs were re-
quested to fill in the case record form, which specifically asked for 
occurrence of strokes, or hospitalizations because of a cerebrovas-
cular event, and death because of a cerebrovascular event (other 
vascular events were also assessed). Afterwards GPs were asked to 
supply all available information about these events (e.g. hospital 
discharge letter) to the study center where two experienced neu-
rologists tried to verify whether there was indeed a stroke. If nec-
essary, the GPs and the hospitals were contacted and a final deci-
sion was made. Events qualified as stroke if common focal symp-
toms lasted longer than 24 h or a definite new focal lesion in brain 
imaging was visualized. Partly due to imprecise or unspecific 
symptom description of transient ischemic attacks, these were
excluded from further analysis. The following cerebrovascular 
events were categorized: total strokes; ischemic and hemorrhagic 
strokes; fatal and nonfatal strokes. All strokes were further veri-
fied and adjudicated by two neurologists independently (S.M. and 
K.B.), who were unaware of PAD status of patients. In case of de-
viating opinions  [27] , consensus was reached by discussion. Par-
ticular attention was paid to the categorization of stroke events 
into hemorrhagic and ischemic  [28] .
 Statistical Analyses 
 Univariate and multivariate Cox regression analyses were per-
formed, and the corresponding hazard ratios (HR, and their 95% 
confidence intervals, CI) were calculated to assess associations 
between PAD (and other risk factors) and 5-year CVD mortality/
morbidity. In addition to PAD (yes/no), or PAD (symptomatic/
asymptomatic) or ABI categories, respectively, the following vari-
ables were included in all multivariate statistical models (each yes 
or no, if not indicated otherwise): age (above/below median), gen-
der (male/female), smoking status (never/ever), BMI (above/below 
30), history of revascularization (coronary/at carotids) or myocar-
dial infarction, history of stroke, presence of diabetes, systolic 
blood pressure per 10 mm Hg (continuous), hypertension medica-
tion, lipid disorders and homocysteine (below/above 4th quintile, 
19.1   mol/l). For calculating the incidence rates, only the first 
event was taken into account. To illustrate possible linear rela-
tions between low ABI values and the risk of CVD deaths or 
events, the ABI was categorized according to the cutoff points 1.1, 
0.9, 0.7 and 0.5. Patients with a history of peripheral revascular-
ization or amputation due to PAD at baseline were included as a 
separate category. Time-to-event distributions in the individual 
categories were summarized with Kaplan-Meier curves.
 Statistical significance was accepted at the two-sided 0.05 lev-
el, and all confidence intervals were computed at the 95% level. 
Statistical analyses were performed with SAS version 9.1 (SAS In-
stitute Inc., Cary, N.C., USA).
 Patient Disposition at Follow-Up 
 At 5 years, the survival status (dead/alive) of all but 4 of the 
6,880 patients was known ( 1 99.9%). In 5,032 of 6,049 patients still 
alive, a clinical examination at study end could be performed, 
whereas in 273 cases information could be obtained only indi-
rectly, e.g. via telephone. From the 309 patients with potential 
strokes reported by the GPs (233 nonfatal strokes, 76 deaths be-
cause of a cerebrovascular event), 185 were confirmed as stroke 
(150 nonfatal strokes, 35 deaths because of a cerebrovascular 
event). Two strokes (1 ischemic) occurred in the 59 patients with 
ABI  1 1.5; one of the patients was diabetic.
 Patients lost to follow-up were included in the corresponding 
time-to-event analyses with censoring at the date of last informa-
tion.
 Results 
 Baseline Characteristics 
 A total of 6,821 patients aged 65 years or older were 
included in the analyses.  Table 1 shows the baseline char-
acteristics of the 5,392 individuals without PAD and the 
1,429 persons categorized as PAD patients (21.0%), of 
whom 836 had asymptomatic PAD (12.3%) and 593 
symptomatic PAD (8.7%). A total of 311 patients, i.e. 113 
(7.9%) in the PAD group and 198 (3.7%) in patients with-
out PAD, had a history of stroke. PAD patients were 
somewhat older than patients without PAD, were more 
commonly current or past smokers, and had a higher bur-
den of concomitant diseases, in particular diabetes mel-
litus.
 Stroke Mortality and Morbidity by PAD Status 
 During the 5-year follow-up (29,915 patient-years, 
PY), 183 patients had a stroke (incl. fatal; 6.1 cases per 
1,000 PY; 95% CI 5.2–7.1). For comparison, the incidence 
per 1,000 PY for a myocardial infarction, a coronary re-
vascularization and/or death because of a cardiovascular 
event was 17.7 (95% CI 16.1–19.3). On the left,  figure 1 
shows the PY and numbers of stroke events, by type (isch-
emic vs. hemorrhagic), and outcomes (nonfatal vs. fatal).
 Fatal strokes (35 cases) were much less frequent than 
nonfatal strokes (149 cases). In patients with PAD, the raw 
incidence of all stroke types per 1,000 PY, with the excep-
tion of hemorrhagic stroke, was about doubled (for fatal 
stroke tripled). The corresponding unadjusted HR were 
2.1 (95% CI 1.5–2.9) for total stroke, 2.4 (95% CI 1.7–3.4) 
for ischemic stroke, 0.9 (95% CI 0.2–2.6) for hemorrhagic 
stroke, 3.4 (95% CI 1.7–6.6) for fatal stroke and 1.9 (95% 
CI 1.3–2.8) for nonfatal stroke.
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 The increased risk of PAD patients for stroke remained 
significant for total stroke, ischemic stroke and fatal 
stroke (but not for hemorrhagic stroke or nonfatal stroke) 
after adjustment for age, history of stroke events, antihy-
pertensive medication, gender and known stroke risk fac-
tors as shown in  figure 1 , on the right. Risk increases after 
adjustment were between 1.4 (nonfatal stroke) and 2.5 
(fatal stroke). Excluding patients with previous strokes 
from analysis, there is no substantial change in the prog-
nostic effect of PAD for ischemic stroke [1.8 (1.2–2.7) vs. 
1.7 (1.2–2.5)].
 Figure 2 illustrates the comparison of asymptomatic 
and symptomatic PAD patients for ischemic stroke. Com-
pared to patients without PAD, the risk increase was 
somewhat higher in asymptomatic PAD patients than in 
symptomatic PAD patients. Differences for all stroke 
types did not reach significance (data not shown).
 Stroke Morbidity and Mortality by ABI Category 
 In the analysis of ischemic strokes by ABI category, 
patients with ABI 1.1–1.5 (3.8 events) and 0.9–1.1 (4.4 
events) had the lowest event rate per 1,000 PY, while with 
decreasing ABI event rates increased substantially ( fig. 2 ). 
This finding is illustrated with event-free survival over 
time by ABI category, in  figure 3 . Similar outcomes were 
found for total stroke, and for nonfatal and fatal stroke.
 Association of Risk Factors and Incident Ischemic 
Stroke 
 In the multivariate analysis of cardiovascular risk fac-
tors ( fig.  4 ), statistically significant predictors for isch-
emic stroke were higher age (defined as above the median 
of 72 years: HR 2.0), history of stroke (HR 1.9), PAD (HR 
1.9), diabetes mellitus (HR 1.5) and systolic blood pres-
sure (per 10 mm Hg: HR 1.1). Conversely, history of re-
Table 1.  Patient characteristics at inclusion, in the total cohort and by PAD status
All patients No/unknown PAD P AD
n % or 
mean 8 SD
n % or 
mean 8 SD
n % or 
mean 8 SD
All 6,821 5,392 1,429
Age 6,821 72.585.3 5,392 72.285.1 1,429 73.985.6
Gender
Female 3,959 58.0 3,187 59.1 772 54.0
Male 2,862 42.0 2,205 40.9 657 46.0
Smoking status
Never 3,687 54.1 3,083 57.2 604 42.3
Past 2,500 36.7 1,888 35.0 612 42.8
Current 634 9.3 421 7.8 213 14.9
BMI 6,816 27.384.1 5,387 27.384.1 1,429 27.484.2
Diabetes mellitus
No/unknown 5,090 74.6 4,172 77.4 918 64.2
Yes 1,731 25.4 1,220 22.6 511 35.8
Hypertension medication
No/unknown 3,311 48.5 2,811 52.1 500 35.0
Yes 3,510 51.5 2,581 47.9 929 65.0
Lipid disorders
No/unknown 1,158 17.0 953 17.7 205 14.3
Yes 5,663 83.0 4,439 82.3 1,224 85.7
History of stroke
No/unknown 6,510 95.4 5,194 96.3 1,316 92.1
Yes 311 4.6 198 3.7 113 7.9
History of revascularization (coronary/at carotids) or myocardial infarction
No/unknown 5,975 87.6 4,854 90.0 1,121 78.4
Yes 846 12.4 538 10.0 308 21.6
Systolic blood pressure 6,821 146822 5,392 144821 1,429 151824
A  total of 59 patients with ABI >1.5 were excluded from the analyses. For definition of PAD, diabetes mel-
litus, lipid disorders etc., see Methods section.
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vascularization (at carotids/coronary) or myocardial in-
farction was not found to be associated with incident 
ischemic strokes, nor was lipid disorders.
 The prevalence of atrial fibrillation, as documented in 
patient charts and physician letters, did not significantly 
differ in stroke patients without PAD (35 patients, 28.9%) 
versus stroke patients with PAD (15 patients, 24.2%, p = 
0.5 in   2 test).
 Discussion 
 We have recently reported a substantially increased 
risk of  all-cause and  cardiovascular mortality after 3-year 
and 5-year follow-ups associated with a low ABI in this 
cohort  [7, 20] . The present analysis indicates that such 
PAD patients also carry a substantially elevated risk for 
ischemic stroke, which is about doubled compared to in-
dividuals without PAD.
 Previously, a series of major community studies of at 
least 3 years’ duration investigated the relative risk in-
crease in incident stroke events in patients with a low ABI 
 ! 0.9 compared to patients without PAD. In the Cardio-
vascular Health Study (5,888 Medicare patients  6 65 
years), the unadjusted relative risk (RR) associated with a 
low ABI was 1.9 (95% CI 1.4–2.7), and the adjusted RR 
was 1.1 (95% CI 0.7–1.7)  [20, 29] . In the Honolulu Heart 
Program (2,767 men aged 71–93 years of Japanese ances-
try), the unadjusted RR was 2.1 (95% CI 1.3–3.5), and the 
adjusted RR was 2.0 (95% CI 1.1–3.5)  [30] . In the ARIC 
study (14,839 men and women aged 45–64 years in 4 US 
communities), the unadjusted RR was 3.3 (95% CI 2.1–
5.3), and the adjusted RR was 1.9 (95% CI 0.8–4.8)  [31] . 
Two other studies that used a slightly different ABI cutoff 
for the PAD diagnosis ( ̂  0.9), namely the Edinburgh Ar-
tery Study (55- to 74-year-old primary-care patients) with 
an adjusted RR of 2.0 (95% CI 1.1–3.8)  [11] , and a small 
Swedish study of 68-year-old men in a community sam-
ple (adjusted RR 2.0; 95% CI 1.1–3.7)  [12] came to similar 
conclusions. Taken together, all these studies found be-
fore adjustment a doubled or tripled stroke risk in pa-
tients with low ABI, and the risk increase in the majority 
 Fig. 1. Stroke events during 5-year follow-up according to various 
definitions and respective adjusted HR in patients with and with-
out PAD. F igures in parentheses are 95% CI. A total of 59 patients 
with ABI >1.5 were excluded from the analyses. One patient had 
a fatal and a nonfatal stroke and was counted in both subgroups. 
For the analysis, only the first event was taken into account. HR 
as a result of a Cox regression analysis: adjusted for diabetes mel-
litus, hypertension medication, systolic blood pressure per 10 mm 
Hg, lipid disorders, age (>median), sex, BMI (≥30), smoking (ever), 
history of revascularization (coronary/at carotids) or myo cardial 
infarction, history of stroke and homocysteine (>4th quintile, 19.1 
μmol/l) at baseline. For definitions, see Methods section. 1 Refer-
ence, n = 5,392. 2 n = 1,429. 3 Not adjusted for history of revascu-
larization (coronary/at carotids) or myocardial infarction because 
of lack of events. 
PY Events
n
Incidence
n/1,000 PY
HR
(adjusted)
Strokes total
PAD no/unknown1 24,048 121 5.0 (4.1–6.0)
1.57 (1.13–2.18)PAD2 5,867 62 10.6 (7.9–13.2)
Ischemic strokes
PAD no/unknown 24,048 97 4.0 (3.2–4.9)
1.73 (1.21–2.46)PAD 5,867 57 9.7 (7.1–12.3)
Hemorrhagic strokes
PAD no/unknown 24,048 19 0.8 (0.4–1.2)
0.70 (0.22–2.15)3PAD 5,867 4 0.7 (0–1.4)
Fatal strokes
PAD no/unknown 26,217 19 0.7 (0.3–1.1)
2.53 (1.24–5.13)PAD 6,581 16 2.4 (1.2–3.7)
Nonfatal strokes
PAD no/unknown 24,048 102 4.2 (3.4–5.1)
1.41 (0.97–2.05)PAD 5,867 47 8.0 (5.7–10.4)
1 2 3 4 5 6
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 Fig. 2. Ischemic stroke according to presence/absence of PAD or 
according to ABI category. F igures in parentheses are 95% CI;
n.a. = not assessed. A total of 59 patients with ABI >1.5 were ex-
cluded from the analyses. HR as a result of a Cox regression anal-
ysis: adjusted for diabetes mellitus, hypertension medication, sys-
tolic blood pressure per 10 mm Hg, lipid disorders, age (>median), 
sex, BMI (≥30), smoking (ever), history of revascularization (cor-
onary/at carotids) or myocardial infarction, history of stroke and 
homocysteine (>4th quintile, 19.1 μmol/l) at baseline. For defini-
tions, see Methods section. 
Patients
n
PY Events
n
Incidence of
ischemic strokes
n/1,000 PY
HR
(adjusted)
All 6,821 29,915 154 5.1 (4.3–6.0)
PAD no/unknown 5,392 24,048 97 4.0 (3.2–4.9) reference
PAD total 1,429 5,867 57 9.7 (7.1–12.3) 1.73 (1.21–2.46)
PAD asymptomatic 836 3,471 36 10.4 (6.9–13.8) 1.91 (1.28–2.86)
PAD symptomatic 893 2,397 21 8.8 (5.0–12.6) 1.51 (0.91–2.51)
PAD symptomatic vs. PAD asymptomatic 0.82 (0.47–1.43)
ABI category
Missing 8 31 0 0 (n.a.)
1.5 ≥ ABI ≥ 1.1 2,172 9,716 37 3.8 (2.5–5.1) reference
1.1 > ABI ≥ 0.9 3,414 15,140 67 4.4 (3.3–5.5) 1.13 (0.73–1.72)
0.9 > ABI ≥ 0.7 800 3,359 30 8.9 (5.7–12.2) 1.54 (0.90–2.62)
0.7 > ABI ≥ 0.5 214 837 12 14.3 (6.2–22.5) 2.32 (1.12–4.80)
ABI <0.5 51 182 3 16.5 (n.a.) 2.53 (0.70–9.09)
History of peripheral 
revascularization or 
amputation (due to 
PAD) at baseline
162 649 5 7.7 (0.9–14.5) 1.42 (0.51–3.91)
1 3 5 82 4 76 9
0.80
0 1 2 3
Time after baseline (years)
4 5
0.85
0.90
0.95
1.00
1.1 ≤ ABI ≤ 1.5 
0.9 ≤ ABI <1.1
Previous peripheral
revascularization or
amputation due to PAD 
ABI <0.5
0.5 ≤ ABI < 0.7
0.7 ≤ ABI < 0.9
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 Fig. 3. Risk of ischemic stroke by ABI cat-
egory. Event-free survival refers to the 
nonoccurrence of ischemic strokes. 
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of these studies, but not all, remained significant after 
adjustment for other risk factors.
 Our study is one of the largest with a relatively high 
number of stroke events. It should be noted that in terms 
of cardiovascular risk, population-based studies as well 
as our study were unequivocal, confirming that a low ABI 
is an independent predictor of future cardiovascular 
events  [8, 20] .
 The present study documents a linear increase in risk 
(lowest in ABI 1.1–1.5) to the 0.7–0.5 category. In the cat-
egory of patients with an ABI  1 1.5 (n = 59), the number 
of strokes (2) was too low to assess whether there is a high-
er risk of these patients with calcified arteries, as has been 
suggested in two previous studies  [32, 33] , who found a 
U-shaped risk curve related to the ABI.
 In our analysis of associations between various known 
cardiovascular risk factors and ischemic stroke, there was 
no significant difference in terms of comorbid atrial fi-
brillation in PAD patients versus non-PAD patients who 
had suffered a stroke. However, the difference in the PAD 
emerged as one of the significant factors, similarly to pre-
vious analyses that documented the link between PAD 
and death due to coronary artery disease  [7] . This result 
clearly contrasts with the Rotterdam study, in which a low 
ABI lost its predictive ability after adjustment for other 
cardiovascular risk factors  [34] . Notably, while previous 
stroke events predicted incident (recurrent) strokes, we 
did not find a relation between prior revascularizations 
(at carotids or coronaries) as indicators of less severe vas-
cular events. In contrast to validated scores and their al-
 Fig. 4. Factors associated with incident ischemic stroke events. 
F igures in parentheses are 95% CI. A total of 59 patients with ABI 
>1.5 were excluded from the analyses. HR as a result of a Cox re-
gression analysis: adjusted for diabetes, hypertension medication, 
systolic blood pressure per 10 mm Hg, lipid disorders, age (>me-
dian), sex, BMI (≥30), smoking (ever), history of revascularization 
(coronary/at carotids) or myocardial infarction, history of stroke 
and homocysteine (>4th quintile, 19.1 μmol/l) at baseline. For def-
initions, see Methods section. 
Patients
n
PY Events
n
Incidence of
ischemic strokes
n/1,000 PY
HR
(adjusted)
PAD no/unknown 5,392 24,048 97 4.0 (3.2–4.9)
1.73 (1.21–2.46)yes 1,429 5,867 57 9.7 (7.1–12.3)
Diabetes mellitus no/unknown 5,090 22,648 97 4.3 (3.4–5.2)
1.54 (1.09–2.17)yes 1,731 7,267 57 7.8 (5.8–9.9)
Age (>median) no 3,696 16,697 54 3.2 (2.3–4.1)
2.03 (1.44–2.86)yes 3,125 13,218 100 7.6 (6.0–9.1)
Homocysteine (>4th no/unknown 5,488 24,317 118 4.9 (3.9–5.8)
1.08 (0.73–1.59)quintile; 19.1 μmol/l) yes 1,333 5,597 36 6.4 (4.3–8.6)
Male sex no 3,959 17,566 82 4.7 (3.6–5.7)
1.14 (0.78–1.66)yes 2,862 12,348 72 5.8 (4.4–7.2)
Smoker (ever) no 3,687 16,436 75 4.6 (3.5–5.6)
1.13 (0.78–1.64)yes 3,134 13,478 79 5.9 (4.5–7.2)
BMI (≥30) no/unknown 5,246 23,080 114 4.9 (4.0–5.9)
1.15 (0.79–1.68)yes 1,575 6,834 40 5.9 (4.0–7.7)
History of revasculari- no/unknown 5,975 26,361 129 4.9 (4.0–5.8) 1.16 (0.73–1.82)
zation (coronary/
at carotids) or myo-
cardial infarction
yes 846 3,554 25 7.0 (4.2–9.8)
History of stroke no/unknown 6,510 28,658 137 4.8 (3.9–5.6)
1.86 (1.09–3.17)yes 311 1,257 17 13.5 (7.0–20.0)
Lipid disorders no/unknown 1,158 4,962 32 6.4 (4.2–8.7)
0.77 (0.51–1.16)yes 5,663 24,953 122 4.9 (4.0–5.8)
Hypertension no/unknown 3,311 14,746 60 4.1 (3.0–5.1)
1.12 (0.79–1.58)medication yes 3,510 15,169 94 6.2 (4.9–7.5)
Systolic blood pressure
per 10 mm Hg
continuous
1.13 (1.05–1.22)
0.5 1.0 1.5 2.0 2.5 3.0 3.5
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gorithms for the prediction of recurrent strokes in the 
long term such as the Stroke Prognosis Instrument I–II 
 [35] or the Essen Stroke Risk Score  [36] , previous myocar-
dial infarction did not predict strokes. Lipid disorders in 
our study were mostly characterized by the intake of 
statins, which might explain the protective effect of the 
condition in the multivariate model.
 Our study has strengths in terms of representativeness 
for the primary care setting, high data quality due to on-
site monitoring of centers, very low attrition rates and 
nearly complete follow-ups concerning life status. How-
ever, some limitations have to be considered. While stroke 
diagnoses taken from hospital or GP records were veri-
fied centrally to the best extent possible, misclassifica-
tions of events cannot be entirely excluded  [28] . However, 
such misclassifications would occur in both groups, and 
our results are consistent with the findings of previous 
smaller studies as described above. Second, data on med-
ication use were only recorded at baseline, but not during 
the follow-up. It is conceivable that physicians increased 
the intensity of antihypertensive, lipid-lowering and/or 
antiplatelet treatment in the newly diagnosed PAD pa-
tients in the absence of blinding, leading to confounding 
due to medical care  [37] . This could have led to an under-
estimation of the risk associated with PAD, but would not 
alter the conclusions drawn from the study. It is more 
likely that GPs did not intensify treatment in PAD pa-
tients, as undertreatment seems to be the rule rather than 
an exception in these patients  [1, 2] .
 Summing up, primary-care patients with (asymptom-
atic or symptomatic) PAD have a substantially increased 
risk of stroke, which was significant for the all-cause, 
ischemic and fatal stroke categories. In the context of oth-
er studies, our findings confirm the value of PAD (and a 
low ABI) for the prediction of incident vascular events. 
Elderly patients in the primary-care setting should be 
screened for PAD to enable stringent treatment of modi-
fiable cardiovascular risk factors to reduce the risk of 
ischemic stroke and other vascular events.
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